Julia Rotow, MD

This segment summarizes practical guidance for patients, providers, and payers, emphasizing the need for comprehensive genomic testing and rapid access to targeted therapies.

This segment analyzes key limitations of current evidence—including the non-randomized design of PHAROS and challenges of cross-trial comparison—while underscoring the ongoing need for better strategies in non-V600E mutations.

This segment examines treatment considerations for patients with CNS involvement, stressing individualized decisions due to limited dedicated CNS data for encorafenib/binimetinib in lung cancer.

This segment centers on key safety takeaways from the PHAROS study and how those findings influence real-world clinical practice when initiating BRAF-MEK-directed therapy.

This segment explores why multiple efficacy endpoints are essential when evaluating targeted therapies and transitions into a discussion of safety outcomes from the PHAROS study.

This segment focuses on the efficacy results from the PHAROS phase II study, highlighting clear differences between treatment-naïve and previously treated patients with BRAF V600E-mutant NSCLC.

This segment reviews the design and patient characteristics of the PHAROS study, a phase II trial evaluating the BRAF-MEK inhibitor combination encorafenib and binimetinib in patients with BRAF V600E-mutant metastatic NSCLC.

The discussion focuses on the unique treatment approach for BRAF V600E–mutant NSCLC, which differs from other oncogenic drivers such as EGFR or ALK that are typically treated with single-agent targeted therapy.

This segment establishes the clinical context for BRAF V600E–mutant metastatic NSCLC, a relatively rare but clinically important subset of lung cancer.